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1063saline transthoracic echocardiography study showed a
signiﬁcantly larger shunt than pre-PFO closure. 3D
TEE demonstrated residual shunting from the supe-
rior aspect of the left atrial disc (white arrow). The
right atrial (RA) 3D TEE view revealed a prominent
ridge of solid tissue, the ER (black dotted line), pre-
venting the RA disc (white dotted line) from resting
ﬂush on the FO because the FO was partially obscured
at its anterosuperior border by the high insertion of
the ER. Flow was seen from the inferior edge of the RA
disc through the PFO, which was “held open” by the
“rigid” device.
A further example of this anatomy is shown in
Figure 1B. To achieve complete PFO closure, we found
either a softer more compliant device (Gore Helex
septal occluder, W. L. Gore & Associates, Inc., Flag-
staff, Arizona) (Figure 1C) or a smaller device where
the left and right atrial discs can be placed indepen-
dently (Premere device from St. Jude Medical, St.
Paul, Minnesota) (Figure 1D) to be better suited. The
identiﬁcation of a prominent ER is essential to guide
optimal device selection.Anna C. Kydd, MD
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and Computed Tomography Angiography for
Prediction of Cardiovascular EventsWe compared coronary magnetic resonance angiog-
raphy (CMRA) and coronary multislice computed
tomography angiography (CTA) for prediction ofcardiac events in patients with suspected or known
coronary artery disease (CAD) scheduled for elective
coronary angiography (ICA).
We included 110 consecutive patients with sus-
pected or known CAD scheduled for ICA, reported in a
previous study (1). Thirty-three (30%) had prior CAD.
Each patient was examined in a clinical 3.0-T cardiac
magnetic resonance (CMR) scanner (Achieva 3
Tesla, Philips, Best, the Netherlands) and a 64-slice
computed tomography scanner (SOMATOM Sensa-
tion 64, Siemens Healthcare, Erlangen, Germany).
Coronary assessment was performed as described
previously (1). Follow-up data were collected by
reviewing clinical records or by phone interviews.
Cardiac events were deﬁned as cardiovascular death,
nonfatal myocardial infarction, need for revasculari-
zation, invasive angiography, or hospitalization
attributable to cardiac causes. Events that occurred in
the ﬁrst 3 months were excluded.
Sixty-two patients (56.4%) had at least 1 signiﬁ-
cant lesion (50% luminal diameter stenosis in
segments $1.5 mm with quantitative ICA as refer-
ence). Thirty-four (30.9%) had 1-vessel disease,
17 (15.5%) had 2-vessel disease, and 11 (10%) had
3-vessel or left main (LM) disease (1). The follow-up
was 40  16 months. Thirty-seven cardiac events
were recorded, including 1 cardiac death (0.9%),
4 myocardial infarctions (3.6%), surgical revasculari-
zation (9 [8.2%]), or percutaneous revascularization
(14 [12.7%]), and ICA or hospitalization (9 [8.2%]).
Seven events that occurred in the ﬁrst 3 months were
excluded; 30 events were analyzed.
No signiﬁcant differences in event-free survival
were observed between coronary CTA and CMRA
(log-rank test p ¼ 0.97). No differences were observed
when the analysis was performed based on the
number of vessels affected (3-vessel or LM disease,
p ¼ 0.97; 2-vessel disease, p ¼ 0.60; and 1-vessel
disease, p ¼ 0.340) or per-vessel (right coronary,
p ¼ 0.79; LM, p ¼ 0.99; left anterior descendent,
p ¼ 0.97; and circumﬂex, p ¼ 0.99). The hazard ratio
was 4.69 (95% conﬁdence interval: 1.80 to 12.24,
p ¼ 0.002) for positive versus negative coronary CTA
and 3.17 (95% conﬁdence interval: 1.36 to 7.36,
p ¼ 0.007) for CMRA (Figure 1).
Our ﬁndings were as follows: 1) the absence of
coronary stenosis in CMRA or coronary CTA identiﬁes
patients at low risk for cardiac events; and 2) in
patients with suspected or known CAD already
scheduled for ICA, CMRA and coronary CTA provide
similar prognostic information on an intraindividual
basis.
The prognostic value of CMRA is not well known.
One study (2) demonstrated more cardiac events in
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FIGURE 1 Kaplan-Meier Curves and Receiver Operating Characteristic Analysis
(A and B) Kaplan-Meier event-free survival curves for patients with (þ) and without () signiﬁcant stenosis on coronary computed tomography
angiography (CTA) and coronary magnetic resonance angiography (CMRA). (C) Curves for patients without signiﬁcant lesions on coronary CTA
and CMRA. Coronary CTA displayed a trend toward a higher performance. (D) Receiver operating characteristic curves for event prediction.
AUC ¼ area under the curve, CI ¼ conﬁdence interval.
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1064patients with stenosis on CMRA. Coronary CTA has
been demonstrated to predict cardiovascular events
(3). We showed no signiﬁcant differences between
CMRA and coronary CTA in prognostic assessment,
although we did not evaluate the incremental utility
of each technique to the other.
Cardiac MR provides prognostic information with
regard to ischemia and viability assessment (4,5).
Coronary angiography could be integrated into MR
protocols to increase its prognostic value, although
this has not been assessed. Our study included
patients with an ICA indication; however, CMRA is
intended for patients with low-intermediate CAD
suspicion who do not necessarily require ICA.
Although 30% of our patients had known CAD, our
results did not change after its exclusion. The small
sample size and number of hard events should be
accounted for when the conclusions are analyzed;
however, in our study, a minimum of 100 patients
was sufﬁcient to demonstrate that coronary CTA and
MR angiography had equal predictive value (power
>90%, McNemar test for noninferiority analysis).Finally, we did not perform a multivariate analysis.
This should be further assessed.
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2013;61:2310–2.Annulus Instead of LVOT Diameter Improves
Agreement Between Echocardiography
Effective Oriﬁce Area and Invasive
Aortic Valve AreaCalculating effective oriﬁce area (EOA) in aortic ste-
nosis (AS) relies on geometric assumptions regarding
the left ventricular outﬂow tract (LVOT). There is no
consensus on the optimal site for LVOT measure-
ment on transthoracic echocardiography (TTE), with
guidelines permitting ﬂexibility (1). Given varied
LVOT morphology and increased ellipticity below the
annulus (2), we hypothesized that EOA calculated
from the annulus diameter—as compared with sub-
annular diameters—would improve agreement with
aortic valve area (AVA) by invasive hemodynamics.
We examined 114 consecutive adult patients with
symptomatic AS referred for transcatheter aortic
valve implantation (TAVI) with complete TTE
and invasive hemodynamics within 60 days, after
exclusion of patients with greater than mild tricuspid
regurgitation or inadequate studies. Two blinded,
independent readers interpreted TTEs, and EOA was
compared using diameters at the annulus and 0.5 and
1.0 cm subannular. LVOT was stratiﬁed as hourglass-
shaped (LVOT diameter 0.5 cm below annulus greater
than annulus diameter) or funnel-shaped (remaining
cases). Invasive AVA was calculated using the Gorlin
equation (mean of 3 thermodilution cardiac output
measurements) and was corrected for the catheter
size.Mean age was 78.9  8.9 years, and 61.4%
(70 of 114) were male. Severe AS by invasive hemo-
dynamics (AVA <1.0 cm2) was present in 87.7% (100
of 114) of patients, whereas the remainder had mod-
erate AS. There was no overall difference between
mean AVA (0.75  0.24 cm2) and EOA using the
diameter at the annulus (0.76  0.23 cm2, p ¼ 0.59;
mean difference 0.01  0.21 cm2, r ¼ 0.61), 0.5 cm
subannular (0.73  0.25 cm2, p ¼ 0.34; mean differ-
ence 0.02  0.23 cm2, r ¼ 0.58), or 1.0 cm subannular
(0.78  0.29 cm2, p ¼ 0.23; mean difference 0.03 
0.27 cm2, r ¼ 0.51) (Figure 1). Agreement within 0.20
cm2 between AVA and EOA was observed in 71.9% (82
of 114) of cases using the annulus diameter, with
reduced agreement using 0.5 cm (62.3%, 71 of 114, p ¼
0.12) or 1.0 cm (56.1%, 64 of 114, p ¼ 0.01) subannular.
In patients with funnel-shaped LVOTs (n ¼ 47),
AVA and EOA using the annulus diameter were
similar (0.74  0.24 cm2 vs. 0.77  0.28 cm2, p ¼ 0.30;
mean difference 0.03  0.21 cm2), whereas EOA was
overestimated using the diameter 0.5 cm (0.83 
0.30 cm2, p ¼ 0.006; mean difference 0.09 
0.22 cm2) and 1.0 cm (0.94  0.34 cm2, p < 0.001;
mean difference 0.20  0.26 cm2) subannular.
Among individuals with hourglass-shaped LVOTs
(n ¼ 67), AVA and EOA using the annulus diameter
were similar (0.76  0.25 cm2 vs. 0.76  0.20 cm2,
p ¼ 0.86; mean difference 0.00  0.21 cm2), whereas
EOA was underestimated using the diameter 0.5 cm
(0.66  0.18 cm2, p < 0.001; mean difference 0.10 
0.20 cm2) and 1.0 cm (0.67  0.20 cm2, p ¼ 0.001;
mean difference 0.09  0.21 cm2) subannular.
This study demonstrates that the EOA calculated
from the annular diameter—rather than the LVOT
diameter 0.5 or 1.0 cm below the annulus—results in
the best agreement with the AVA determined by inva-
sive hemodynamics in AS patients referred for TAVI.
Although the overall mean differences between AVA
and EOA using alternate diameters were not statisti-
cally signiﬁcant, comparisons by LVOT morphology
demonstrate meaningful differences. Speciﬁcally,
mean EOA using the annular diameter was similar to
AVA regardless of LVOT morphology, whereas use of
an LVOT diameter below the annulus resulted in sig-
niﬁcant and meaningful overestimation of EOA in
patients with funnel-shaped LVOTs and underesti-
mation of EOA in those with hourglass-shaped LVOTs.
Study limitations include the use of AVA as the
reference standard; although this has recognized
limitations (3), it has historically been considered a
reference standard (2,3). The study was limited to
patients referred for TAVI, as invasive valve hemo-
dynamics are often not routinely performed in other
cohorts; therefore, a majority of subjects had severe
